The funding round was led by Apeiron Investment Group, which contributed $20 million (approx €18 million), along with other investors, including renowned global family offices and institutions.
Notably, Apeiron Investment Group is the family office Christian Angermayer (40), who co-founded a biotech company in 1999 -Alnylam. It’s worth mentioning that the Apeiron Investment Group focuses mainly on three main areas – financial services, technology, and life sciences.
Focus on early-stage startups!
Furthermore, Presight Global Venture Opportunities Fund will invest mainly in the United States and selectively in Asia and Europe. According to the founders, Presight generally invests in early-stage venture rounds. Additionally, the company will help startups with connections and knowledge needed to expand into Europe as well.
Family office of Christian Angermayer!
For the uninitiated, Presight Capital is the international venture arm of Apeiron Investment Group, the family office of German entrepreneur and investor Christian Angermayer.
Angermayer founded Presight with Fabian Hansen early this year. Through Presight, this will be the first time Apeiron will be managing outside money.
To date, Presight has made nine investments out of which five of them disclosed publicly:
- Terran Biosciences: Focused on neurological and mental illness
- Peptilogics: Developing treatments to address drug-resistant bacterial infections
- Enclear Therapies: Focused on neurodegenerative disease
- SmithRX: Aims to replace pharmacy benefit managers
- Left Coast Ventures: A cannabis company
While a lot of focus is being given to the biotech industry, Angermayer, on the other hand, wants to invest across different industries.
Stay tuned to Silicon Canals for more updates in the tech startup world.